Pyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street Zen

Pyxis Oncology (NASDAQ:PYXS) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Other analysts also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Royal Bank Of Canada decreased their target price on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating for the company in a research report on Thursday, December 18th. Stifel Nicolaus cut their price target on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, March 24th. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research note on Tuesday, March 24th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $7.00.

Pyxis Oncology Price Performance

Shares of NASDAQ PYXS opened at $1.31 on Friday. The firm has a market cap of $82.31 million, a PE ratio of -1.02 and a beta of 1.45. The company’s fifty day simple moving average is $1.49 and its 200 day simple moving average is $2.50. Pyxis Oncology has a 12-month low of $0.83 and a 12-month high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings results on Monday, March 23rd. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.06. The company had revenue of $11.04 million during the quarter, compared to the consensus estimate of $0.13 million. On average, equities analysts predict that Pyxis Oncology will post -1.04 earnings per share for the current year.

Institutional Investors Weigh In On Pyxis Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of PYXS. Maia Wealth LLC bought a new position in Pyxis Oncology during the 4th quarter valued at $25,000. Engineers Gate Manager LP bought a new stake in shares of Pyxis Oncology in the 4th quarter worth $26,000. Fox Run Management L.L.C. purchased a new stake in shares of Pyxis Oncology in the fourth quarter valued at about $26,000. Avanza Fonder AB bought a new position in shares of Pyxis Oncology during the fourth quarter valued at about $31,000. Finally, XTX Topco Ltd bought a new position in shares of Pyxis Oncology during the second quarter valued at about $40,000. 39.07% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology News Roundup

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” and materially lifted multiple forward EPS forecasts (FY2026, FY2027, FY2028 and projected FY2030 profitability) and bumped several quarterly estimates — signaling improved multi‑year expectations and a $7 price target. These revisions are a bullish catalyst for upside longer term. HC Wainwright Lifts Earnings Estimates for Pyxis Oncology HC Wainwright Reaffirms Buy for Pyxis Oncology
• Neutral Sentiment: Market data shows an apparent zero reported short interest for March (likely a reporting artifact); this provides no reliable directional signal for near‑term price pressure.
• Negative Sentiment: Insider selling: Director Rachel Humphrey disclosed sales (most recently 13,896 shares at about $1.03). Insider exits can be viewed negatively by investors even if done for personal/liquidity reasons. Insider Selling Disclosure
• Negative Sentiment: Some sell‑side shops trimmed upside: Stifel lowered its price target (reducing implied upside), a sign that not all analysts are uniformly bullish. That can temper buying interest. Stifel Lowers Expectations for Pyxis Oncology
• Negative Sentiment: Within HC Wainwright’s note there was a downward revision to Q2‑2026 EPS (to -$0.36 from -$0.32), introducing mixed near‑term guidance despite the more positive multi‑year outlook — likely contributing to short‑term selling pressure.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.